Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Doorgaan beter dan afbouwen van glucocorticoïden na lage ziekteactiviteit
aug 2020 | RA